Andy Studna, Senior Editor

Dr. C.K. Wang, Chief Medical Officer for COTA discusses the use of real world data, the results of a recent survey by COTA, and his own career journey.

Martin Gouldstone, Chief Business Officer of Life Sciences, Sensyne, updates us on the status of AI in data used for clinical research, the difference between ethical AI vs. AI, and what Sensyne is trying to achieve in this space.

Micah Lieberman, Executive Director, Conferences for CHI and Co-Founder, VP, Community and Business Development of ClinEco talks about what to expect at the upcoming SCOPE conference in February, tips on how to get the most out of your experience, life during the pandemic, and much more.

Jane Parnes, Executive Medical Director, Early Development at Amgen talks about her own career path, how clinical trials are being conducted at Amgen, as well as her experience as a female leader in STEM.

Dr. Lise Lund Kjems, Chief Medical Officer at Cyclo Therapeutics, talks about Cyclo’s investigational therapy for Niemann-Pick Disease Type C and gives insight into rare disease drug development, with an emphasis on ensuring trial design includes holistic and specific patient concerns.

Bob Chaplinsky, Director Corporate Quality Compliance at UCB, discusses the trajectory of quality management systems in pharma, the importance of change management when implementing new systems, and staying on top of compliance and regulatory changes on a global scale.

Mary Costello, Head of Site and Investigator Network at Medable, and Pat Larrabee, CEO of Rochester Clinical Research, discuss their extensive careers in the clinical trials industry, as well as talk about their article in our October issue, “Why Siteless Trials Won’t Work.”

Jaydev Thakkar, COO of Biofourmis, talks about decentralized trials, clinical research as a care option, digital therapeutics, and what Biofourmis is working on.

Raj Indupuri, CEO of eClinical Solutions, talks about the build vs. buy pendulum faced by CROs, the pros and cons of each model, and more.

Brad Power, Founder of CancerHacker Lab, speaks about his innovative crowdsourcing approach to help cancer patients, his own battle with lymphoma, and the unique challenges brought to the table by clinical trials in oncology.

Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.

Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.

John Reites, CEO of THREAD Research, discusses how his organization is adapting to decentralized trials and efforts they're taking to increase patient recruitment.

Dr. Theodore Leng, MD, Medical Advisor to Verana Health and Director of Clinical and Translational Research at the Byers Eye Institute at Stanford, Stanford University Medical School, talks about a recent study he led and presented in early May at the Association for Research in Vision and Ophthalmology Meeting.

New BDO CRO Insights Report reveals high rate of CRA turnover and what organizations are doing to combat it.

Co-conveners of the newly formed Decentralized Trials & Research Alliance, Amir Kalali, MD and Craig Lipset discuss the alliance as well as how COVID-19 has impacted the industry.

Recent webcast addresses what organizations can do to prepare for the next revision of ICH E6.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Sujay Jadhav, global vice president, study start-up, Oracle Health Sciences, spoke with ACT on how study start-up has been impacted by the pandemic and what its future holds beyond COVID.

Jody Casey of Elligo Health Research gives insight into the issue of diversity in trials and what needs to be done to correct it.